Capecitabine Tablet, Film Coated
Product Images NDC 60687-149

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 60687-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp14994

Capecitabine 500 mg film-coated tablet shown from both sides. The oblong, pink tablet is imprinted with '77' on one side and '191' on the other. Millimeter measurement scales are visible adjacent to the tablet edges for size reference.*

FDA Label Image

Carton

Capecitabine 500 mg film-coated tablets by American Health Packaging. The label indicates 20 tablets per package (2 x 10), with directions for pharmacists to dispense with a patient information leaflet. It includes storage instructions, safety warnings, and notes that the drug is cytotoxic and prescription only.*

FDA Label Image

Cockroft And Gault Equation

A text panel displaying a formula for calculating creatinine clearance for males, which involves subtracting age from 140, multiplying by body weight in kilograms, and dividing by the product of 72 and serum creatinine in mg/dL.*

FDA Label Image

Figure 1

A survival curve chart comparing treatment groups for Capecitabine and 5-FU + Leucovorin over months since randomization. The x-axis shows time in months, and the y-axis shows survival probability ranging from 0.0 to 1.0. Two lines represent the survival rates: a solid line for Capecitabine and a dashed line for 5-FU + Leucovorin, with corresponding numbers at risk displayed below the x-axis.*

FDA Label Image

Figure 2

A survival curve chart comparing two treatment groups: Capecitabine and 5-FU + Leucovorin. The x-axis shows months since randomization from 0 to 96. The y-axis shows survival probability ranging from 0.0 to 1.0. Two survival curves are displayed, with Capecitabine as a solid line and 5-FU + Leucovorin as a dashed line. Below the x-axis, the number of patients at risk in each group is listed at various time points.*

FDA Label Image

Figure 3

A survival curve graph comparing estimated probability over time (in days) between two treatment groups: 5-FU plus Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/sqm twice daily intermittent. The y-axis represents estimated probability from 0 to 1, and the x-axis shows time in days up to 1500. The two curves depict survival trends for each treatment group.*

FDA Label Image

Figure 4

A Kaplan-Meier survival curve comparing estimated probabilities over time (days) for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph shows survival probabilities declining from 1.0 to near 0 over approximately 700 days, with arrows indicating specific time points at 128 and 186 days.*

FDA Label Image

Figure 5

A survival curve graph showing estimated probability over time in days for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks (solid line). The x-axis is labeled Time (Days) and the y-axis Estimated Probability. Two vertical arrows indicate specific time points at approximately 352 and 442 days.*

FDA Label Image

Metabolic Pathway

Diagram showing the enzymatic conversion pathway of Capecitabine into its metabolites 5'-DFCR, 5'-DFUR, and ultimately 5-FU. The chemical structures of each compound are illustrated with arrows indicating transformation steps catalyzed by carboxylesterase, cytidine deaminase, and deoxythymidine phosphorylase enzymes.*

FDA Label Image

Structure

Chemical structure of capecitabine, showing the molecular arrangement including a fluorinated pyrimidine ring and a sugar moiety.*

FDA Label Image

Structural Formula (Image 01)

Capecitabine 500 mg film-coated tablet labels from American Health Packaging, each marked as a cytotoxic agent. The labels include the product name, strength, formulated as tablet USP, and barcode with associated NDC (60687-149). Batch lot and expiry date fields are indicated but not filled in. The labeler location is Columbus, Ohio.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.